about
Immunological interactions in radiotherapy-opening a new window of opportunityPelvic exenteration: experience from a rural cancer center in developing world.Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation).Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers.Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline.An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients.Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers.An audit of cytoreductive surgeries in ovarian cancer from a rural based cancer center.Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.Competing risk: An illustration with aspiration pneumonia in head and neck cancer patients undergoing radical radiotherapy: A biostatistician's perspective.Expectations and preferences for palliative chemotherapy in head and neck cancers patients.Head and neck cancer in geriatric patients: Analysis of the pattern of care given at a tertiary cancer care center.Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?Impact of thrombosis on standard treatment in solid tumors.Predictivity of human papillomavirus positivity in advanced oral cancer.A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer.Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?Letter to the editor: second, third, and fourth head and neck tumors. A progressive decrease in survival.Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy.Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer.Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3-4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitoComparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers.Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.Development and validation of a questionnaire to measure preferences and expectations of patients undergoing palliative chemotherapy: EXPECT questionnaire.Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinomaBayesian state-space modeling in gene expression data analysis: An application with biomarker predictionComparison of Radioiodine uptake by Gamma Camera and Thyroid uptake probe-based methodologies and Diagnostic Radioiodine Scan in Differentiated thyroid carcinomaQuality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patientsPhase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung CancerClinical biomarker discovery by SWATH-MS based label-free quantitative proteomics: impact of criteria for identification of differentiators and data normalization method.Survey of the State of Implementation of the American Society of Clinical Oncology/Oncology Nursing Society Safety Standards for Chemotherapy Administration in IndiaPilot study of single-day distress screening with the NCCN distress thermometer to evaluate the feasibility of routine distress screening in tertiary cancer center in rural IndiaA prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neckIn regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial"
P50
Q26767178-E36A5ABE-510C-4E83-B6B4-2627CAFB7BDDQ35109484-EDAE84D6-B1EC-4F45-B616-D2BCA081BA7DQ36587228-882A943A-3607-49E4-863C-AF19358D2FB2Q37458763-A8357748-0FF8-46B2-81DC-B877EDC9045CQ37737013-1F3C7910-7476-47AB-A7A3-0077DFEE600AQ38267883-319E1916-9897-42A5-A72A-F9754B38B5DDQ38613121-1DF5143B-070B-4CA2-9C16-20939AD85DEFQ38856442-6B600777-D4D3-476D-ACA8-92A33A547FCDQ38897438-8997443D-4C17-415A-9042-54F2787CB97BQ39029730-BDC29441-A57D-4A89-9F97-232382A9DEDAQ39029735-87908A90-F689-479D-B2BB-5E4BEB3DD391Q39121599-1FE4C4D5-04C4-4408-AFF2-D15F3C923DF7Q39162828-4459624F-2FBD-4A38-BD21-2AB05851BB23Q39976737-D358FEB3-871B-46B3-9BD7-A35069ECF50AQ40030519-CB9F03A2-3073-4096-BEB6-B480CB346F30Q40493710-6A621261-B28D-4C62-8428-A7D027DF0D31Q40781061-CF74DD86-2DD0-4CB1-8C16-BCA430B4D983Q40906512-38B43134-89D8-4AEE-A4A7-4E3C266F14AEQ44019291-CE1F44E4-221A-4A8C-8FA9-3845BC7830DCQ44579561-80610221-8A8B-4703-B61F-89A885219389Q47102129-B353D3C2-2597-4989-B070-BBC1B8FBF772Q47135157-7F15E3FF-FCA2-411A-AA89-E48FC2344030Q47377006-897E6135-231A-4571-98DC-0353DB2D111FQ49331557-9964E0B6-AE18-4878-9B8D-1D51A888903EQ49331682-70F3D65E-71E7-4633-AA81-DEB9F9DED5B6Q49800454-F685D4B5-C49E-4BF6-9A82-4117AB1A4D76Q49965638-FF9A1D69-ABC1-424E-B27D-85530D031F40Q50004154-4561585B-F301-4AC4-A323-ED853888ADACQ50960271-7BACDB27-4D99-4EDB-A0A9-34AD755B47BBQ54990179-4FF21267-4FE2-4BCE-918E-5242642C796AQ56524519-CAC5D1C3-5533-4E1D-B6DC-CA5AEDB09F3EQ57121737-B88C292E-E095-4089-9036-C950122F9FD6Q58566719-B4ED8A13-9C35-48A3-98E4-A29B7A7DD831Q59134279-BBE78185-FBA1-40E5-A2AE-72A8F528707FQ64246131-7CA815DD-6C4D-4CF1-B1DD-807D2D6A980BQ64890699-AAB365AE-8D62-41AF-8021-71C428F2F7BBQ85892134-1D007DB4-8CA0-4E15-BAD2-7D5D7C44192BQ86384497-43264F6C-E766-4075-BA7A-44513D4A6316Q86509605-0162E01B-98B1-4D97-9017-826A7AA6C25FQ87287597-7FD29102-BA05-473D-99D9-F2A3D6921C00
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Atanu Bhattacharjee
@ast
Atanu Bhattacharjee
@en
Atanu Bhattacharjee
@es
Atanu Bhattacharjee
@nl
Atanu Bhattacharjee
@sl
type
label
Atanu Bhattacharjee
@ast
Atanu Bhattacharjee
@en
Atanu Bhattacharjee
@es
Atanu Bhattacharjee
@nl
Atanu Bhattacharjee
@sl
prefLabel
Atanu Bhattacharjee
@ast
Atanu Bhattacharjee
@en
Atanu Bhattacharjee
@es
Atanu Bhattacharjee
@nl
Atanu Bhattacharjee
@sl
P106
P1153
52563214400
P31
P496
0000-0002-5757-5513